Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Korea's firstIntegrated Stem Cell Bank
Bio Insurance
Global CHA Network
| Classification | Placental-derived MSCs (PLX-PAD) | ||
| Indication | Intermittent Claudication (IC) | ||
| Significance | - First placenta-based cell therapy in Korea | ||
| Symptom | - Causes arm and leg pain by poor blood circulation - Causes narrowing or blocking vessels by Atherosclerosis | ||
| Progress | - R&D Pipeline introduction through alliance with Pluristem Therapeutics of Israel in 2013 - Exclusive licensing to conduct clinical trial in Korea (Phase 2 clinical trial in progress) ㆍPhase 2 trial ongoing in the U.S, Germany and Israel (Intermittent Claudication) ㆍPhase 1 trial completed in the U.S. and Germany (Critical Limb Ischemia) | ||
| Procedure | - Intramuscular injection | ||
| Outcome | - Clinical trial in progress | ||
